Key Points
Mumbai: Aurobindo Pharma anticipates a hit of $20 million in the ongoing January-March quarter due to a temporary pause of manufacturing and distribution activities at its crucial Eugia Unit-III formulation facility in Telangana, following certain red flags raised by the US drug regulatory agency in the recently concluded inspections...
The company said it is planning to resume manufacturing operations in a phased manner starting with non-aseptic lines..
The US regulatory agency issued Form 483 with 9 observations against the facility at the conclusion of the inspection on February 2. The company, as an "abundant caution", put on hold manufacturing at certain lines...
Subramanian said the company anticipates to resume production on non-aseptic lines from the end of the month and phased resumption on aseptic lines following an assessment which may take about 1-2 months...
You might be interested in
Cipla shares fall nearly 7% after Pithampur unit gets 8 observations from USFDA
20, Feb, 23India Business News: The US Food and Drug Administration (USFDA) conducted a current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility from Febr
USFDA issues Form 483 with 5 procedural observations to Torrent Pharma's Gujarat unit
12, Dec, 23New Delhi, Dec 12 (PTI) Torrent Pharmaceuticals Ltd on Tuesday said the US health regulator has issued Form 483 with five procedural observations after inspecting its oral manufacturing facility situated at Bileshwarpura in Gujarat. As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm’s management at the conclusion of […]
Gland Pharma share price rise 6% after USFDA completes inspection of Hyderabad facility
24, Nov, 23Gland Pharma share price witnessed a 6.5% surge on Friday following the company's announcement that the United States Food and Drug Administration (USFDA) had successfully concluded its inspection of the Pashamylaram facility in Hyderabad.
Aurobindo Pharma's Pen-G unit under PLI to begin commercial production in April-June 2024 quarter
14, Mar, 24India Business News: Aurobindo Pharma's Penicillin-G facility in Kakinada, Andhra Pradesh, will start commercial production in Q1 FY 2024-25. The facility, with an investm